GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Biocept BIOCQ · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 30 Oct 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Biocept — daily BIOCQ Delayed
Market value
$171
Last close × shares
Volume
238
Shares, 30 Oct 2026

About Biocept

Its shares trade under the ticker BIOCQ. It has been listed since 5 February 2014. In the fiscal year to 31 December 2022, it reported revenue of $25.9m and a net loss of $32.1m. At that date it held total assets of $30.9m and shareholders' equity of $8.9m.

Biocept, Inc. is an oncology laboratory service company, which engages in the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. The company is headquartered in San Diego, California. The company went IPO on 2014-02-05. The firm focuses on developing and commercializing clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor deoxyribonucleic acid (DNA) from blood and cerebrospinal fluid (CSF). Its product is branded and trademarked under the name CNSide. CNSide encompasses a suite of cellular and molecular technologies intended to aid medical professionals in CSF analysis and central nervous system (CNS) disease management in patients with solid tumors. The company offers and conducts its commercialized diagnostic assays, which include cell capture and enumeration, immunocytochemistry, fluorescent in situ hybridization (FISH), and next generation sequencing (NGS). The company has commercialized its CNSide assays for detecting and characterizing many different carcinomas and melanoma. These assays utilize its dual cellular and ctDNA technology platforms and provide biomarker analysis from a patient’s CSF sample.

Figures and description from our data supplier, not checked against the company's own report.

More about Biocept →

Latest on Biocept

Our reporting

We have not reported on Biocept yet.

Next results

24 Nov 2026

Due on 24 Nov 2026.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Biocept's ticker?

Biocept trades as BIOCQ on its US listing, under ISIN US09072V6002.

What was Biocept's last closing price?

0.00 on 30 Oct 2026. The figure is in USD and is never converted.

When does Biocept next report results?

Results are expected on 24 Nov 2026, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.